Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Ken W who wrote (403)	9/3/2002 3:48:50 PM
From: Ditchdigger	Respond to of 23958

will have to take a look, moving some cash into janus overseas for a play on tomorrow. Overseas markets have been hit hard 2 days in a row..hoping us markets get a morning bounce and help move the overseas markets up a bit for a bounce play<g>..;^)DD EDIT, changed my mine, I'll stay with the cash for now...major damage being done to the charts..

To: Ken W who wrote (403)	9/3/2002 4:25:39 PM
From: Ditchdigger	Respond to of 23958

Speaking of CPHD<g> a little more news out today "Press Release Source: Cepheid Cepheid and Children's Medical Center of Dallas to Develop Rapid Diagnostic Methods for Infectious Diseases in Children Tuesday September 3, 7:01 am ET SUNNYVALE, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD - News), today announced that it has been selected to participate in a program to develop rapid diagnostic methods for improving the diagnosis of infectious diseases in children. ADVERTISEMENT The project, which is a collaborative effort including Cepheid, Children's Medical Center of Dallas and The University of Texas Southwestern Medical Center at Dallas, involves the development of rapid diagnostic test protocols, procedures, and reagents using Cepheid's Smart Cycler and GeneXpert® platforms. Dr. Beverly Rogers, chief of pathology at Children's and professor of pathology at UT Southwestern, is leading the program which will focus on the development of rapid nucleic acid testing methods for enterovirus and herpes simplex virus which are major causes of meningitis, and Bordetella pertussis, the bacteria that causes whooping cough. Despite immunization programs, this disease continues to be a serious health concern. The one-year Centers for Disease Control and Prevention grant to Children's Medical Center of Dallas will total $435,000, part of which will be used to purchase GeneXpert systems and cartridges. "The GeneXpert® system is ideally suited to this type of test because of its speed, its automated sample processing capability, and its ability to detect multiple DNA sequences in the same reaction. Scheduled for market availability in 2003, the GeneXpert® is designed to provide a fully automated genetic assessment result, sample in -- answer out," said Kurt Petersen, Cepheid president and chief operating officer. Dr. Rogers remarked, "Innovations in diagnostic testing that incorporate molecular biology into the routine care of the patient are ringing in the millennium. The Cepheid GeneXpert system is the first 'walk-away' instrument that combines all of the aspects of the PCR, so that a health-care worker can take a sample from a patient, place the sample into the instrument, and have an answer within an hour. The rapid diagnosis of childhood meningitis, sepsis, or even antibiotic resistance will soon be available in 'real-time,' that is 24 hours a day/seven days a week. There is great potential to identify infections faster, treat patients better, and save patient admissions to the hospital, resulting in cost savings to the health-care system."